Ibtini and venetoclax get FDA approval for treatment of chronic lymphocytic leukemia

recently, the New England Journal of Medicine recently launched a major study from the MD Anderson Cancer Center, in which two existingdrugs,(http://a beautiful "combination punch" in the treatment of high-risk and elderly patients with chronic lymphocytic leukemia (CLL) have produced stunning resultsBoth ibrutinib and venetoclax have been approved by theFDA(http://for the treatment of chronic lymphocytic leukemia (CLL), which was also available in China two years agoThe 2-year study included 80 untreated CLL patientsThe median age of patients is 65 years old, 30% are elderly patients over 70 years old, and 92% are high-risk patients with genetic abnormalitiesThe patient received ibutinib monotherapy for 3 cycles, then added venetoclax to continue the combination of treatment for 24 cyclesMost patients can observe partial remission after the first 3 ibitinib treatment cyclesAs venetoclax joins the treatment, the(http://of micro-residual
diseases is improving as more and more patients reach full remissionAfter 12 treatment cycles, 88% of patients have achieved complete remission, and 61% of patients who cannot detect microresidual disease Both elderly or high-risk patients respond to treatment 　　The data showed that 60 percent of patients in the treatment had low white blood cell counts, similar to those reported in other (http:// trial s combination therapy Compared to single-drug therapy, the combination of ibitinib and venetoclax did not show new safety problems and, as the researchers predicted, using ibutinib prior to treatment also significantly reduced the risk of developing tumor-dissolving syndrome after taking venetoclax